The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.
 
David R. Gandara
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Genentech; Guardant Health; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Joachim Von Pawel
Consulting or Advisory Role - Clovis Oncology (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Roche (Inst); Vertex (Inst)
 
Richard N. Sullivan
No Relationships to Disclose
 
Aslaug Helland
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
 
Ji-Youn Han
No Relationships to Disclose
 
Santiago Ponce Aix
No Relationships to Disclose
 
Achim Rittmeyer
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche/Genentech
 
Fabrice Barlesi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Merck Serono; Novartis; Pfizer; Pierre Fabre; Pierre Fabre
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Roche/Genentech (Inst)
 
Toshio Kubo
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca
 
Jerome H. Goldschmidt
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Celgene
 
Mayank Gandhi
Employment - Genentech
 
Cindy Yun
Employment - Genentech
Stock and Other Ownership Interests - Roche
Research Funding - Genentech
 
Wei Yu
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche/Genentech
 
Christina Matheny
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Stanford University
Travel, Accommodations, Expenses - Genentech/Roche
 
Pei He
Employment - Genentech/Roche
Stock and Other Ownership Interests - Allergan (I); Amgen; Gilead Sciences (I); Roche
 
Alan Sandler
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Marcus Ballinger
Employment - Genentech
Stock and Other Ownership Interests - Exelixis; Roche; Sunesis Pharmaceuticals
 
Louis Fehrenbacher
Research Funding - Roche/Genentech (Inst)